文献速递临床试验与 GCP流行病学与生物统计

宽松心率控制与严格心率控制治疗心房颤动:丹麦心房颤动(DanAF)随机临床试验的统计分析计划

Lenient rate control versus strict rate control for atrial fibrillation: a statistical analysis plan for the Danish Atrial Fibrillation (DanAF) randomized clinical trial.
PubMed 文献 · Trials · 2023-04-01

丹麦心房颤动试验是一项随机、多中心、两组、优效性试验,比较严格心率控制与宽松心率控制对持续性或永久性心房颤动患者的疗效。主要结局为SF-36问卷躯体健康成分评分,计划纳入350名受试者,所有分析基于意向性治疗原则,该统计分析计划在入组完成前和数据可及前发布以增加试验有效性。

要点

  • 丹麦心房颤动试验比较严格与宽松心率控制对持续性或永久性心房颤动患者的疗效。
  • 主要结局为SF-36问卷躯体健康成分评分,计划纳入350名受试者。
  • 所有分析基于意向性治疗原则,连续变量采用线性回归校正部位、心房颤动类型、左心室射血分数和基线值。

核心结论

  • 该统计分析计划在入组完成前和数据可及前发布,旨在增加丹麦心房颤动试验的有效性。

研究设计与样本

  • 丹麦心房颤动试验是一项随机、多中心、两组、优效性试验,比较严格心率控制与宽松心率控制对纳入时患有持续性或永久性心房颤动患者的疗效。
  • 计划纳入350名受试者,基于SF-36问卷躯体健康成分评分的最小重要差异3分、标准差10分、统计功效80%(β为20%)和可接受的I型错误风险5%计算。

主要发现

  • 主要结局为SF-36问卷躯体健康成分评分。
  • 所有次要、探索性和超声心动图结局均为假设生成性。
  • 所有结局的分析将基于意向性治疗原则。
  • 连续结局将采用线性回归分析,校正部位、纳入时心房颤动类型(持续性/永久性)、左心室射血分数(≥40%或<40%)和结局基线值(均作为固定效应)。
  • 统计显著性阈值定义为p值0.05,临床显著性评估将基于样本量和功效估计中定义的预期干预效应,统计和临床显著性阈值将根据Jakobsen等人提出的5步程序进行评估。

关键数值与推荐

  • 统计显著性阈值定义为p值0.05。
  • 临床显著性评估基于样本量和功效估计中定义的预期干预效应。
  • 统计和临床显著性阈值将根据Jakobsen等人提出的5步程序进行评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A key decision in the treatment of atrial fibrillation is choosing between a rhythm control strategy or a rate control strategy as the main strategy. When choosing rate control, the optimal heart rate target is uncertain. The Danish Atrial Fibrillation trial is a randomized, multicenter, two-group, superiority trial comparing strict rate control versus lenient rate control in patients with either persistent or permanent atrial fibrillation at inclusion. To prevent bias arising from selective reporting and data-driven analyses, we developed a predefined description of the statistical analysis. METHODS: The primary outcome of this trial is the physical component score of the SF-36 questionnaire. A total of 350 participants will be enrolled based on a minimal important difference of 3 points on the physical component score of the SF-36 questionnaire, a standard deviation of 10 points, a statistical power of 80% (beta of 20%), and an acceptable risk of type I error of 5%. All secondary, exploratory, and echocardiographic outcomes will be hypothesis-generating. The analyses of all outcomes will be based on the intention-to-treat principle. We will analyze continuous outcomes using linear regression adjusting for "site," type of atrial fibrillation at inclusion (persistent/ permanent), left ventricular ejection fraction (≥ 40% or < 40%), and the baseline value of the outcome (all as fixed effects). We define our threshold for statistical significance as a p-value of 0.05 and assessments of clinical significance will be based on the anticipated intervention effects defined in the sample size and power estimations. Thresholds for both statistical and clinical significance will be assessed according to the 5-step procedure proposed by Jakobsen and colleagues. DISCUSSION: This statistical analysis plan will be published prior to enrolment completion and before any data are available and is sought to increase the validity of the DANish Atrial Fibrillation trial. TRIAL REGISTRATION: Clinicaltrials.gov NCT04542785. Registered on Sept 09, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cold IM, Feinberg JB, Brandes A, et al. Lenient rate control versus strict rate control for atrial fibrillation: a statistical analysis plan for the Danish Atrial Fibrillation (DanAF) randomized clinical trial. Trials. 2023. PMID: 37005636. doi:10.1186/s13063-023-07247-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。